Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
Mol Pharm. 2010 Oct 4;7(5):1466-77. doi: 10.1021/mp100125b. Epub 2010 Sep 2.
Dissolution testing is frequently used to determine the rate and extent at which a drug is released from a dosage form, and it plays many important roles throughout drug product development. However, the traditional dissolution approach often emphasizes its application in quality control testing and usually strives to obtain 100% drug release. As a result, dissolution methods are not necessarily biorelevant and meaningful application of traditional dissolution methods in the early phases of drug product development can be very limited. This article will describe the development of a biorelevant in vitro dissolution method using USP apparatus 4, biorelevant media, and real-time online UV analysis. Several case studies in the areas of formulation selection, lot-to-lot variability, and food effect will be presented to demonstrate the application of this method in early phase formulation development. This biorelevant dissolution method using USP apparatus 4 provides a valuable tool to predict certain aspects of the in vivo drug release. It can be used to facilitate the formulation development/selection for pharmacokinetic (PK) and clinical studies. It may also potentially be used to minimize the number of PK studies, and to aid in the design of more efficient PK and clinical studies.
溶出度测试常用于确定药物从剂型中释放的速度和程度,它在药物产品开发的各个阶段都起着重要作用。然而,传统的溶出度方法通常强调其在质量控制测试中的应用,并且通常努力达到 100%的药物释放。因此,溶出度方法不一定与生物相关,在药物产品开发的早期阶段,传统溶出度方法的实际应用可能非常有限。本文将介绍使用 USP 仪器 4、生物相关介质和实时在线 UV 分析开发生物相关的体外溶出度方法。将介绍几个制剂选择、批间变异性和食物影响方面的案例研究,以展示该方法在早期制剂开发中的应用。使用 USP 仪器 4 的这种生物相关的溶出度方法为预测体内药物释放的某些方面提供了有价值的工具。它可用于促进药代动力学(PK)和临床研究的制剂开发/选择。它还可能有助于减少 PK 研究的数量,并有助于设计更有效的 PK 和临床研究。